TrialClinical cancer research : an official journal of the American Association for Cancer Research2026

T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.

Robin K Kelley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.